Imatinib Eugia

Imatinib, the active ingredient in Imatinib Eugia, is a tyrosine kinase inhibitor presented as an oral formulation for systemic use. It is indicated for chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor, targeting malignant cells that express BCR‑ABL, c‑KIT or PDGFR. GNH USA supplies Imatinib Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing disease control in several hematologic and solid tumours. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): helps achieve remission and disease control. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and prolongs progression‑free survival.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower limbs. - Muscle cramps: occasional painful muscle contractions. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: signs of reduced heart function. - Pulmonary hypertension: increased pressure in lung arteries. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Use of Imatinib requires careful monitoring and patient counseling. - Blood count monitoring: perform regular CBC to detect cytopenias. - Liver function assessment: check hepatic enzymes before and during therapy. - Cardiac evaluation: assess baseline cardiac status and monitor for heart failure. - Pregnancy avoidance: drug is contraindicated in pregnancy (Category D). - Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can affect absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Diuretics (e.g., furosemide): increased risk of fluid retention. - QT‑prolonging agents (e.g., sotalol): may heighten risk of cardiac arrhythmias.